Buy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell Engagers
JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on December 27.Stay Ahead of the ...